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ABSTRACT: A series of dibasic des-hydroxy 2 receptor agonists has been prepared and evaluated for potential as inhaled
ultra-long acting bronchodilators. Determination of activities at the human -adrenoreceptors demonstrated a series of
highly potent and selective 2 receptor agonists that were progressed to further study in a guinea pig histamine-induced
bronchoconstriction model. Following further assessment by; onset studies in guinea pig tracheal rings and human bron-
chial rings contracted with methacholine (guinea pigs) or carbachol (humans), duration of action studies in guinea pigs
after intratracheal (i. t.) administration and further selectivity and safety profiling AZD3199 was shown to have an excel-
lent over all profile and was progressed into clinical evaluation as a new ultra-long acting inhaled 2 receptor agonist with
rapid onset of action.
The β2-adrenoceptor (β2AR) is a member of the class A,
G protein-coupled receptor (GPCR) family and is widely
distributed in the respiratory tract and particularly in air-
way smooth muscle. Agonists of this receptor are very
effective bronchodilators1 and, in combination with either
an inhaled corticosteroid or a muscarinic antagonist,
β2AR agonists form the current standard for treatment for
both asthma2 and chronic obstructive pulmonary disease
COPD. 3 The ‘first generation’ β2AR agonists e.g. salbuta-
mol were classed as short duration β2AR agonists requir-
ing multiple daily dosing. These were followed by ‘second
generation’ compounds (e.g. salmeterol or formoterol)
that exhibited longer duration of action amenable to
twice-daily dosing. Although these second generation
inhaled β2AR agonists have proven very effective, poor
compliance combined with ineffective control of noctur-
nal asthma have been recognized as issues limiting their
clinical effectiveness. To address these concerns ‘third
generation’ ultra-long acting inhaled β2AR agonists, de-
signed to have once-a-day duration of action, have been
described4 including olodaterol5, and the launched prod-
ucts vilanterol6 and indacaterol 7,-9 (Figure 1).
The inhaled route to deliver β2AR agonists directly to
the lung is used in order to both maximize the bronchodi-
lator activity whilst minimizing systemic exposure of the
compounds. 10 In the clinical setting, the ability to deliver
efficacy combined with an acceptable separation from the
Figure 1: A selection of known 2AR agonists and sibe-
nadet - a dual D2 dopamine receptor, β2-AR agonist. 
β2AR systemic-mediated side-effects is paramount in de-
fining the predicted human dose. Therefore, a fine bal-
ance is required, where the drug candidate combines long
retention in the target organ, thus enabling a long dura-
tion of action at the β2AR, combined with rapid clearance
from the systemic circulation through the rapid elimina-
tion of either parent compound or associated metabolites
after systemic redistribution of the compound from the
lung tissues.
There has been much debate about the various pro-
posed strategies for the rationalization of agents that ex-
hibit a sustained duration of action when applied topical-
ly to the lung and these hypotheses have been used to
explain the observed differences in the duration of action
seen in preclinical models. Examples of these rationalisa-
tions include amongst others:
The diffusion microkinetic theory: where high membrane
partitioning of lipophilic bases into membrane phospho-
lipids is used to explain the long duration of action. 11
The exosite binding theory: where it is proposed that a
portion of the 2AR agonist (e.g. the lipophilic 4-
phenylbutoxyhexyl group of salmeterol) interacts at a
remote binding site in the β2-adrenoceptor away from the
catechol binding site, and in doing so, holds the com-
pound in close proximity to the receptor. 12
High agonist intrinsic activity: resulting from high recep-
tor occupancy giving prolonged pharmacological effect. 13
Receptor kinetics: where slow receptor off-rates have
been proposed to lead to enhanced duration of action in
both inhaled 2-agonists and inhaled muscarinic M3 re-
ceptor antagonists. 14
Reduction in solubility and permeability: where slow dis-
solution into the airways smooth muscle affords the po-
tential for extended lung retention. 15
In addition to the aforementioned concepts, scientists
from AstraZeneca recently published key concepts for
extending the duration of action through optimization of
the pharmacokinetics (DMPK) of the inhaled therapy. 16
Coupled in part with the above hypotheses, increases in
lipophilicity17 have been shown to be an important pa-
rameter in delivering compounds with an extended dura-
tion of action. Along with modulation in lipophilicity, it
has been shown that the incorporation of a dibasic phar-
macophore within the compounds, leads to an increase in
the duration of action of the β2AR agonists. However, it
has also been suggested that as you increase lipophilicity
then onset of action may be delayed.
A medicinal chemistry hypothesis was put in place to
design and test a series of dibasic compounds, with a
range of lipophilicities in order to determine if lipophilic
dibasic compounds could have a short onset of action
whilst retaining a once-a-day profile.
In addition to optimizing both the duration of action
and fast onset we monitored potential systemic β2AR ag-
onist side-effects through β2AR-induced hypokalemia, an
effect that is caused by increasing cellular uptake of po-
tassium secondary to 2AR stimulation of sodi-
um/potassium ATPase. The sodium/potassium ATPase is
found predominantly on skeletal muscle and has a strong
association with tremor. As a consequence, we decided to
pursue plasma potassium levels as a marker of systemic
β2AR agonist side-effects. At the outset of the project, we
set the goal to identify an inhaled β2AR agonist that was,
well-tolerated, combined a rapid onset of action, compa-
rable to formoterol to achieve better patient compliance 18
and would provide bronchoprotection from once-a-day
dosing.
We wish to report the discovery of AZD3199 a new β2AR
agonist that was designed to combine these project re-
quirements.19 Recently we communicated the discovery
of the new series of β2AR agonists that was devoid of the
C-1 hydroxy group that is present in most β2AR agonists
20
and it has been shown both by ourselves and later by oth-
ers that incorporation of a second basic group into the
β2AR agonist template leads to compounds that demon-
strate longer duration of action due in part to an increase
in membrane partitioning. 21,22 Design hypotheses were
formulated to substitute the amide group (R2) with a
range of aminoalkyl groups with the aim of generating a
new series of potent β2AR agonists that possessed a long
duration of action. Gratifyingly, the strategy delivered a
range of dibasic compounds that maintained both the
high potency and efficacy at the β2AR (compare potency
of compounds 1 and 2 in Table 1). Exploration of the
group R2 showed that a range of basic groups were ac-
commodated without detrimental effect on potency (2-6,
8-11) however, due to balancing overall properties, com-
pounds containing the N,N-diethylamino ethyl group
such as for compound 2 was chosen for further optimiza-
tion. Within this series, limited exploration of the
phenethyl group (R3) showed a surprising effect on effica-
cy (cf examples 2, 12-16) and eventually 12 (AZD3199) was
progressed for further evaluation. Interestingly, the in-
stallation of the chiral C-1 hydroxy group had little effect
on potency and agonism (cf examples 2 and 3; 4 and 16),
and these C-1 hydroxy containing compounds were not
progressed further.
Pharmacological selectivity margins were calculated
relative to the human β2 cAMP potency determined in
H292 cells. Surprisingly, the incorporation of the basic
group (R2) gave compounds with an excellent 2-AR selec-
tivity and AZD3199 has greater than 1000-fold binding
selectivity over β1 and β3 ARs (Chart 1).
Chart 1: Binding selectivity for AZD3199 vs 1 and 3
Radio ligand competition binding assays were determined
for [125I]-iodocyanopindolol binding to membranes express-
ing beta adrenergic receptors. Compound inhibition was
determined following incubation for 2 h at 22°C and ex-
pressed as percentage inhibition relative to the control.
Further selectivity profiling against alpha adrenorecep-
tors (1D), D2 dopamine receptors (D2s) demonstrated
high selectivity for AZD3199 (Table S1 supplementary da-
ta). AZD3199 was greater than 100-fold selective over the
D2s receptor and 50-fold selective against the α1D receptor
and showed no agonism at this receptor even though the
Table 1: Potency and intrinsic activity at the human β2AR.
Compound number R1 R2 R3 2 potency pEC50# IA*
1 H nBu phenethyl 8.8 0.9
2 H -(CH2)2NEt2 phenethyl 8.1 0.9
3 OH -(CH2)2NEt2 phenethyl 8.4 1.0
4 OH -(CH2)2NEt2 3-chlorophenethyl 8.4 0.9
5 H -(CH2)2NMe2 phenethyl 8.2 1.0
6 H -(CH2)3NH2 phenethyl 6.5 0.5
7 H -(CH2)3NMe2 phenethyl 7.8 1.0
8 H -(CH2)3N(Me)iPr 3-chlorophenethyl 8.3 0.8
9 H -(CH2)3N(Me)Et 3-chlorophenethyl 8.0 0.8
10 H -(CH2)3N(Me)cyPr 3-chlorophenethyl 8.1 0.8
11 H -(CH2)2-piperidin-1-yl 3-chlorophenethyl 7.9 0.7
12 H -(CH2)2NEt2 2-(naphthalen-1-yl)ethyl 8.2 0.8
13 H -(CH2)2NEt2 2-(naphthalen-2-yl)ethyl 8.0 0.5
14 H -(CH2)2NEt2 3-fluorophenethyl 8.1 0.8
15 H -(CH2)2NEt2 3-methoxyphenethyl 8.1 0.6
16 H -(CH2)2NEt2 3-chlorophenethyl 8.2 0.7
β2AR agonism was performed in H292 cells (bronchial epithelial cell line) expressing the human β2 adrenergic receptor.
Functional activity was determined by measuring accumulation of intracellular cAMP using AlphaScreenTM. The compounds
were incubated for 1 h at 22°C. *IA (Intrinsic activity) measured relative to formoterol (pEC50 8.6, IA = 1).
recombinant calcium assay employed was considered to
be a high receptor reserve system relative to human vas-
cular tissue. At the D2s receptor AZD3199 had 32-fold
selectivity and was a partial agonist with respect to sibe-
nadet (a dual D2 dopamine receptor, β2-AR agonist). The 
agonist potency of AZD3199 at D2s was 100-fold less than
sibenedet (pEC50 = 8.7). In contrast to the other com-
pounds (see Table S1 supplementary data), which were all
full agonists at the β1AR, AZD3199 showed no agonism at
the β1AR even though the β1 recombinant assay used in
this study was considered to be a high receptor reserve
system when compared with human in vitro tissue exper-
iments in the literature.
AZD3199 was shown to have high potency and intrinsic
activity for the β2AR when assessed for different species
across sources and assay formats (see Table S2 supple-
mentary data). The functional activity at the guinea pig
β2AR was determined for AZD3199 and other reference
compounds by measuring relaxation of tracheal rings pre-
constricted with methacholine in an organ bath. The po-
tency was measured as the EC50 concentration (Table 2).
Table 2: Potency β2-adrenoceptor agonism in isolated
guinea pigs tissue.
Compound Guinea pigs pA50 Guinea pigs
intrinsic activity
AZD3199 8.0 0.8
indacaterol 7.7 0.7
formoterol 8.8 0.9
salmeterol 7.7 0.5
salbutamol 6.7 0.6
Onset of relaxation was measured in vitro using guinea
pig tracheal rings and human bronchial rings contracted
with methacholine (guinea pigs) or carbachol (humans).
22 The EC50 concentration was given and the relaxation
followed over time. The time taken to reach 90% of the
final relaxation was defined as the onset time (Chart 2).
Chart 2: Onset of relaxation of AZD3199 as measured
using guinea pig tracheal rings contracted with 1 µM
methacholine.
A single concentration of AZD3199 was given (at or about
the pEC50 concentration) and the relaxation was followed
over time. After AZD3199 had reached a plateau isoprenaline
was added to confirm that the concentration of AZD3199
used was at EC50 for the tissue. Finally addition of 10µM so-
talol was used to demonstrate reversibility of the response.
AZD3199 was shown to have a fast onset time, compa-
rable to formoterol, in both guinea pigs (22 min) and hu-
mans (11 min), significantly faster than that of salmeterol
(Table 3).
Table 3: Potency and onset time of β2-adrenoceptor
agonism in isolated tissue.
Compound Guinea
pig onset
time
(min)
Human
onset
time
(min)
cLogP Type
AZD3199 22 11 6.0 Dibasic
1 90 n/d 4.5 Monobasic
7 6 n/d 3.7 Dibasic
14 13 n/d 4.9 Dibasic
16 11 n/d 5.5 Dibasic
sibenadet 58 n/d 2.5 Monobasic
indacaterol 77 49 3.0 Monobasic
formoterol 23 13 1.3 Monobasic
salmeterol 90 t/s 3.1 Monobasic
salbutamol 3 19 0.1 Monobasic
n/d = not determined; t/s = onset time too slow to meas-
ure
AZD3199 and other selected reference compounds were
progressed to the guinea pig histamine-induced broncho-
constriction model – a well characterized species for
modeling human lung disease. 24 AZD3199 was given and
a clear dose-response curve was seen (Chart S1 supple-
mentary material), the ED80 dose was determined as
27g/kg (46.7nmol/kg). Propanolol (1mg/kg i.v.) reversed
this bronchoprotection confirming that the activity was
mediated via 2 receptors.
A plot of lipophilicity (clogP) as a function of guinea pig
onset time showed a very interesting correlation and
demonstrated that for monobasic compounds, a strong
correlation exists between increasing onset time with in-
creasing lipophilicity. However, data suggests that for
dibasic compounds, a much reduced onset time could be
achieved with compounds that have increased lipophilici-
ty (Chart 3).
Chart 3: A plot of guinea pig onset time vs cLogP for a
selection of monobasic or dibasic compounds.
Based on encouraging in vitro profiles [rat intrinsic
clearance (105 l/min/million cells)] as well as good level
of potency and intrinsic activity in guinea pig tissues,
AZD3199 was progressed to in vivo rat intra-venous (i.v.)
pharmacokinetic (PK) profiling in order to determine the
terminal half-life. Indeed, in the course of this project it
was shown that in vivo rat plasma i.v. t1/2 can be used as a
predictor of in vivo duration in the bronchoprotection
guinea pig model following intra-tracheal (i.t.) dosing (cf
plasma t1/2>10h for 24h pharmacokinetic duration).
25,26
AZD3199 has i.v. plasma terminal half-lives of 11, 17 and 18
h in rats, guinea pigs and dogs respectively and combined
with high volumes of distribution (Vz) 23 (rats), 22 (guin-
ea pigs) and 17 (dogs) L/Kg afforded confidence of seeing
a long duration of action. Therefore, based on its overall
profile, AZD3199 was selected for further progression to
duration studies in a guinea pig bronchoprotection mod-
el. The lung terminal half-life was predicted from the rat
i.v. dosing giving confidence of potential for u.i.d. dosing.
The low oral availability of AZD3199 in both rats and dogs
(F<2%) would limit any systemic exposure due to swal-
lowed fraction.
The durations of action of AZD3199 and assorted refer-
ence compounds were measured in guinea pigs by the i.t.
route. Guinea pigs were given the ED80 dose of compound
and at various time points after dosing the inhibition of
histamine-induced bronchoconstriction were measured.
AZD3199 retained 58% bronchoprotection 24h after i.t.
dosing, significantly different to control animals. The re-
sults for AZD3199, indacaterol, formoterol and salmeterol
are shown (Chart 4). AZD3199 clearly had a longer dura-
tion of action than formoterol and salmeterol and a simi-
lar duration of action to indacaterol.
Chart 4: Duration of action studies in guinea pigs for
AZD3199 and a selection of standard compounds.
β2AR agonists have several mechanistic side effects due
to activation of peripheral β2 receptors: tachycardia, QTc
changes, hypertension, hypokalaemia, tremor and hyper-
glycaemia; and several of these were measured after ad-
ministration of salbutamol. From these experiments
plasma potassium was chosen as the marker of choice.
The effects were investigated using infusions of salbuta-
mol, formoterol and AZD3199 in anaesthetized guinea
pigs. The infusions were designed to give a constant
plasma level between 30-60 min after the start of the infu-
sion. Dose-related changes in plasma potassium and oth-
er markers were seen as expected. Potassium levels were
compared at 60 min and plotted against the plasma level
of compound, corrected for plasma protein binding and
efficacy (see Chart S2 supplementary data). At the lowest
plasma level AZD3199 produced a significantly smaller
reduction in plasma potassium compared to formoterol;
at all other plasma levels there were no differences be-
tween the compounds. These data suggest that in guinea
pigs, the mechanistic side effects of AZD3199 are no worse
than formoterol and are significantly better at low plasma
levels.
AZD3199 was prepared according to the method out-
lined in Scheme 1. The commercial compound 17 was re-
acted with the acid chloride prepared in situ from acid
1827 to afford alcohol 19. A 2-step oxidation followed by a
reductive amination procedure with the known amine
2028 afforded 12 (AZD3199) in reasonable over all yield.
Scheme 1: The chemical synthesis of AZD3199.
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Reagents and conditions a) 18 + (COCl)2 (1.1 mol eqiv), di-
methyl formamide (cat.), CH2Cl2, rt, 15 h. Concentrate and
add to 17, Hunig’s base (2 mol eqiv), CH2Cl2, rt, 20 h (75%).
b) i) dimethyl sulfoxide (2.2 mol eqiv), CH2Cl2, -78
oC, add
(COCl)2 (1.1 mol eqiv), stir 15 min ii) add 19, stir 15 min, iii)
add triethylamine (5 mol eqiv) and warm to rt 90 min iv) 20
in CH2Cl2, sodium triacetoxyborohydride (2 mol eqiv), rt
(27%).
In summary, a new series of dibasic C-1 des-hydroxy 7-
hydroxy benzthiazolone β2AR agonists have been de-
signed to combine high potency, long duration of action
and fast onset of action. From the design series, AZD3199
was shown to be highly selective (>1500 fold) for the hu-
man β2AR (pEC50 7.9±0.12 (n=8)) over human β1 and β3-
ARs. Further profiling demonstrated AZD3199 to be high-
ly potent when dosed in vivo in a guinea pig histamine-
induced bronchoconstriction model, exhibiting long du-
ration of action amenable to a once-a-day dosing regi-
men. We have demonstrated that a short onset time can
be achieved within the series through combining high
lipophilicity and two basic groups. Utilizing plasma po-
tassium levels in a guinea pig model as a marker of poten-
tial 2AR-induced systemic side effects, AZD3199 pro-
duced, at the lowest plasma level, a significantly smaller
reduction in plasma potassium compared to formoterol;
at all other plasma levels there were no differences be-
tween the compounds. These data suggest that in guinea
pigs, the mechanistic side effects of AZD3199 are no worse
than formoterol and are significantly better at low plasma
levels. In conclusion AZD3199 is a new ultra-long acting
inhaled β2AR agonist and further work will be disclosed
shortly.
ASSOCIATED CONTENT
Supporting Information. Synthetic procedures, analytical
data, tables S1, S2 and S3 Charts S1 and S2 including proce-
dures for pharmacological activities. “This material is availa-
ble free of charge via the Internet at http://pubs.acs.org.”
AUTHOR INFORMATION
Corresponding Author
*E-mail address: michael.stocks@nottingham.ac.uk
Present Address
† Centre for Biomolecular Sciences, School of Pharma-
cy, the University of Nottingham, University Park, Not-
tingham. NG7 2RD, UK.
Author Contributions
All authors have given approval to the final version of the
manuscript.
ACKNOWLEDGMENT
We thank Dr Richard Lewis, John Steele, Mike Bernstein and
Peter Sjö for assistance in submitting the communication.
ABBREVIATIONS
β2AR, β2-adrenoceptor; GPCR G Protein-coupled receptor;
COPD, chronic obstructive pulmonary disease.
REFERENCES
1. Fuso, L.; Mores, N.; Valente, S.; Malerba, M.; Montuschi, P.
Long-acting beta-Agonists and their association with In-
haled corticosteroids in COPD. Curr. Med. Chem. 2013, 20,
1477-1495.
2. Walker, J. K. L.; Penn, R. B.; Hanania, N. A.; Dickey, B. F.;
Bond. R. A. New perspectives regarding β(2)-adrenoceptor 
ligands in the treatment of asthma. Br. J. Pharm. 2011, 163
18-28.
3. Cazzola, M; Page, C. P.; Rogliani, P.; Matera, M. G. 2-
agonist therapy in lung disease. Amer. J. Resp. and Critical
Care Medicine 2013, 187, 690-696.
4. Matera M. G.; Cazzola M. Ultra-long-acting beta2-
adrenoceptor agonists: an emerging therapeutic option for
asthma and COPD? Drugs 2007, 67, 503-515.
5. Bouyssou, T.; Hoenke, C.; Rudolf, K.; Lustenberger, P.; Pes-
tel, S.; Sieger, P.; Lotz, R.; Heine, C.; Buettner, F. H.;
Schnapp, A.; Konetzki, I. Discovery of olodaterol, a novel
inhaled β2-adrenoceptor agonist with a 24 h bronchodilato-
ry efficacy Bioorg. Med. Chem. Lett. 2010, 20, 1410-1414.
6. Procopiou, P. A.; Barrett, V. J.; Bevan, N. J.; Biggadike, K.;
Box, P. C.; Butchers, P. R.; Coe, D. M.; Conroy, R.; Emmons,
A.; Ford, A. J.; Holmes, D. S.; Horsley, H.; Kerr,F.; Li-Kwai-
Cheung, A-M.; Looker, B. E.; Mann, I. S.; McLay, I. M.; Mor-
rison, V. S.; Mutch, P. J.; Smith, C. E.; Tomlin, P. Synthesis
and structure-activity relationships of long-acting β2 adren-
ergic receptor agonists incorporating metabolic inactiva-
tion: an antedrug approach. J. Med. Chem. 2010, 53, 4522–
4530.
7. Davies, S. L.; Castaner, J. Indacaterol Drugs of the Future,
2005, 30, 1219-1224.
8. Roig, J.; Hernando, R.; Mora, R. Open. Resp. Med. J., 2009, 3,
27-30.
9. Baur, F.; Beattie, D.; Beer, D.; Bentley, D.; Bradley, M.;
Bruce, I.; Charlton, S. J.; Cuenoud, B.; Ernst, R.; Fairhurst, R.
A.; Faller, B.; Farr, D.; Keller, T.; Fozard, J. R.; Fullerton, J.;
Garman, S.; Hatto, J.; Hayden, C.; He, H.; Howes, C.; Janus,
D.; Jiang, Z.; Lewis, C.; Loeuillet-Ritzler, F.; Moser, H.; Reil-
ly, J.; Steward, A.; Sykes, D.; Tedaldi, L.; Trifilieff, A.; Tweed,
M.; Watson, S.; Wissler, E.; Wyss, D. The identification of
indacaterol as an ultralong-acting inhaled β2-adrenoceptor 
agonist J. Med. Chem. 2010, 53, 3675-3684.
10. Mortimer, K. J.; Harrison, T. W.; Tang, Y.; Wu, K.; Lewis, S.;
Sahasranaman, S.; Hochhaus, G.; Tattersfield, A. E. Plasma
concentrations of inhaled corticosteroids in relation to air-
flow obstruction in asthma. Br. J. Clin. Pharm. 2006, 62, 412-
419.
11. Anderson, G. P.; Lindén, A.; Rabe, K. F. Why are long-acting
beta-adrenoceptor agonists long-acting? Eur. Respir. J. 1994,
7, 569-578.
12. Green, S. A,; Spasoff, A. P.; Coleman, R. A.; Johnson M.;
Liggett, S. B. Sustained activation of a G protein-coupled re-
ceptor via "anchored" agonist binding. Molecular localiza-
tion of the salmeterol exosite within the 2-adrenergic re-
ceptor. J Biol Chem. 1996, 39, 24029-24035.
13. Bao, Y.; Horst, L. Action mechanism of long-acting bron-
chodilators. Acta Pharm. Sinic. 1998, 20, 191-196.
14. Deyrup, M. D.; Nowicki, S. T.; Richards, N. G. J.; Otero, D.
H.; Harrsison, J. K.; Baker, S. P. Structure-affinity profile of
8-hydroxycarbostyril-based agonists that dissociate slowly
from the beta2-adrenoceptor. Arch. Pharmacol. 1999, 359,
168-177.
15. Patton, J. S.; Byron, P. R. Inhaling medicines: delivering
drugs to the body through the lungs. Nature Rev. Drug Dis-
covery 2007, 6, 67-74.
16. Cooper, A. E.; Ferguson, D.; Grime, K. Optimization of
DMPK by the inhaled route: challenges and approaches.
Current Drug. Met. 2012, 13, 457-473.
17. Alikhani, V.; Beer, D.; Bentley, D.; Bruce, I.; Cuenoud, B. M.;
Fairhurst, R. A.; Gedeck, P.; Haberthuer, S.; Hayden, C.; Ja-
nus, D.; Jordan, L.; Lewis, C.; Smithies, K.; Wissler, E. Long-
chain formoterol analogues: an investigation into the effect
of increasing amino-substituent chain length on the β2-
adrenoceptor activity. Bioorg. Med. Chem. Lett. 2004, 14,
4705-4710.
18. White, M. V.; Sander, N. Asthma from the perspective of
the patient. J. Allergy Clin. Immunol. 1999, 104, s47-52.
19. Kuna P.; Ivanov Y.; Trofimov, V. I.; Saito, T.; Beckman, O.;
Bengtsson, T.; Jorup, C.; Maltais, F. Efficacy and safety of
AZD3199 vs formoterol in COPD: a randomized, double-
blind study. Resp. Research. 2013, 14, 64.
20. Stocks, M. J.; Alcaraz L.; Bailey A.; Bonnert, R.; Cadogan, E.;
Christie J.; Connolly, S.; Cook A.; Fisher A.; Flaherty A.; Hill,
S.; Humphries A.; Ingall A.; Jordan S.; Lawson M.; Mullen A.;
Nicholls D; Paine S.; Pairaudeau G.; St-Gallay S.; Young A.
Design driven HtL: The discovery and synthesis of new high
efficacy β₂-agonists. Bioorg. Med. Chem. Lett. 2011, 21, 4027-
4031.
21. Austin, R. P.; Barton, P.; Bonnert, R. V.; Brown, R. C.; Cage,
P. A.; Cheshire, D. R.; Davis, A. M.; Dougall, I. G.; Ince, F.;
Pairaudeau, G.; Young, QSAR and the rational design of
long-acting dual D2 -receptor/2-adrenoceptor agonists. J.
Med. Chem. 2003, 46, 3210-3220.
22. Alcaraz, L.; Bailey, A.; Cadogan, E.; Connolly, S.; Jewell, R.;
Jordan, S.; Kindon, N.; Lister, A.; Lawson, M.; Mullen, A.;
Dainty I.; Nicholls, D.; Paine, S.; Pairaudeau G.; Stocks, M.
J.; Thorne, P.; Alan Young, A. From libraries to candidate:
the discovery of new ultra long-acting dibasic β₂-
adrenoceptor agonists. Bioorg. Med. Chem. Lett. 2012, 22,
689-695.
23. Procopiou, P. A.; Barrett,V. J.; Biggadike, K.; Butchers, P. R.;
Craven, A.; Ford, A. J.; Guntrip,S. B.; Holmes,D. S.; Hughes,
S. C.; Jones, A. E.; Looker, B. E.; Mutch, P. J.; Ruston, M.;
NeedhamD.; Smith C. E. Discovery of a rapidly metabo-
lized, long-acting β2 adrenergic receptor agonist with a 
short onset time incorporating a sulfone group suitable for
once-daily dosing. J. Med. Chem. 2014, 57, 159−170. 
24. Walland, A.; Palluk, R.; Burkard, S.; Hammer, R. Compensa-
tion of muscarinic bronchial effects of talsaclidine by con-
comitant sympathetic activation in guinea pigs. Eur.J.
Pharmacol. 1997, 330, 213-219.
25. Connolly, S.; Alcaraz, L.; Bailey, A.; Cadogan, E.; Christie, J.;
Cook, A. R.; Fisher, A. J.; Hill, S.; Humphries, A.; Ingall, A.
H.; Kane, Z.; Paine, S.; Pairaudeau, G.; Stocks, M. J.; Young,
A. Design-driven LO: the discovery of new ultra long acting
dibasic β2-adrenoceptor agonists. Bioorg. Med. Chem. Lett.
2011, 21, 4612-4616.
26. Tayab, Z. R.; Hochhaus, G. Pharmacokinet-
ic/pharmacodynamic evaluation of inhalation drugs: appli-
cation to targeted pulmonary delivery systems. Expert.
Opin. Drug. Deliv. 2005, 2, 519-532.
27. Bailey, A.; Bonnert, R.; Flaherty, A.; Pairaudeau, G.; Stocks,
M. 2007, WO 2007027133.
28. Giles, M. E.; Thomson, C.; Eyley, S. C.; Cole, A. J.; Goodwin,
C. J.; Hurved, P. A.; Morlin, A.J. G.; Tornos, J.; Atkinson, S.;
Just, C.; Dean, J. C.; Singleton, J. T.; Longton, A. J.; Wood-
land, I.; Teasdale, A.; Gregertsen, B.; Else, H.; Athwal, M. S.;
Tatterton, S.; Knott, J. M.; Thompson, N.; Smith, S. Devel-
opment of a manufacturing process for Sibenadet hydro-
chloride, the active ingredient of Viozan. J. Org. Process
Res. Dev. 2004, 8, 628-642.
7
